Chapel Hill, N.C. –October 7, 2014 – EpiCypher announces the award of five grants for Histone Peptide Array Screening Services to researchers at Indiana University, Memorial Sloan Kettering Cancer Center, The University of Florida, The University of Montreal and The Structural Genomics Consortium as part of their first annual grant program in support of chromatin biology and epigenetics research. The scientific founders of EpiCypher reviewed each grant application and selected the winners, each of whom will receive histone modification screening services employing EpiCypher’s world-class EpiTitan™ Histone Peptide Arrays, along with a statistical analysis of their protein’s or antibody’s histone modification binding profile.
The grantees are: Levi Blazer, Ph.D., Structural Genomics Consortium; El Bachir Affar, Ph.D., University of Montreal; Omar Abdel-Wahab, M.D., Memorial Sloan-Kettering Cancer Center; Feng-Chun Yang, Ph.D., Indiana University School of Medicine; and Daiqing Liao, Ph.D, University of Florida. The grant recipients and their respective organizations will work individually but collaboratively with EpiCypher’s scientific team to help answer each project’s fundamental biological question.
EpiCypher is dedicated to giving researchers access to the highest quality, most productive approaches for more meaningful investigations into chromatin biology and epigenetics research. “We look forward to introducing these winners to the many benefits of our transformative products and incorporating them into their research so they can experience their advantages to chromatin research first hand,” says EpiCypher CEO Sam Tetlow.
About EpiCypher
Pioneering the Science of Epigenetics™
A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.
EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com
Contacts:
Sam Tetlow, CEO
EpiCypher, Inc.
919-627-7882 (direct)
sam@epicypher.com
Karen Michailo
EpiCypher
Pioneering the Science of Epigenetics TM
919-349-3687
Help employers find you! Check out all the jobs and post your resume.
